Search clinical trials for: GMT

Total 1174 results

Eli Lilly and Company

Completed

A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine

Cancer

United States
Eli Lilly and Company

Completed

A Study for Japanese Participants With Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

Japan
Eli Lilly and Company

Completed

A Study of LY2216684 in Healthy Females

Depressive Disorder, Major

United States
Eli Lilly and Company

Completed

A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors

Major Depressive Disorder

United States
Eli Lilly and Company

Completed

A Study of LY2216684 in Participants With Impaired Hepatic Function

Depressive Disorder, Major

United States
Eli Lilly and Company

Completed

A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel

Major Depressive Disorder

United States
Eli Lilly and Company

Completed

A Study of LY2216684 and Digoxin in Healthy Subjects

Major Depressive Disorder

United States
Eli Lilly and Company

Terminated

A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or Lymphoma (JZAR)

Lymphoma | Advanced Cancer

United Kingdom
Eli Lilly and Company

Completed

Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer

Non-Small-Cell Lung Cancer

Germany, Italy
Eli Lilly and Company

Completed

A Study to Evaluate the Effect of Clarithromycin on LY2216684

Depressive Disorder, Major

United States
Eli Lilly and Company

Completed

A Single Dose Study of LY2605541 in Participants With Liver Impairment

Hepatic Insufficiency | Diabetes Mellitus, Type 2 | Healthy Volunteers

Germany, Hungary
Eli Lilly and Company

Completed

Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer

Cancer

United States
Eli Lilly and Company

Completed

A Study of Insulin Peglispro in Healthy Male Japanese Participants

Healthy Volunteers

Japan
Eli Lilly and Company

Completed

A Study of LY2605541 in Healthy Participants

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Study of LY2605541 in Healthy Participants and in the Elderly

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment

Hepatic Insufficiency

United States
Eli Lilly and Company

Completed

Study of Food on Evacetrapib (LY2484595) in Healthy Participants

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Study of Evacetrapib With Selected Statins in Healthy Chinese Participants

Healthy Volunteers

China
Eli Lilly and Company

Completed

A Study of Evacetrapib in Japanese and Non-Japanese Participants

Healthy Volunteers

United Kingdom
Eli Lilly and Company

Completed

A Study of Evacetrapib in Healthy Female Participants

Healthy Volunteers

United States
Eli Lilly and Company

Terminated

A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia

Hypercholesterolemia

Japan
Eli Lilly and Company

Completed

A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Study of Evacetrapib (LY2484595) in Healthy Participants

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Study of Evacetrapib and Digoxin in Healthy Participants

Healthy Volunteers

United States
Eli Lilly and Company

Terminated

A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia

Hypercholesterolemia

Japan
Eli Lilly and Company

Completed

A Study of Evacetrapib (LY2484595) in Participants With Severe Renal Impairment and in Healthy Participants

Cardiovascular Disease

United States
Eli Lilly and Company

Completed

A Study to Compare Two Forms of LY2608204 in Healthy People

Healthy Volunteers

Singapore
Eli Lilly and Company

Completed

A Study of Evacetrapib in Healthy Participants

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Phase 1 Study of LY2787106 in Cancer and Anemia

Anemia

United States
Eli Lilly and Company

Completed

Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Study of LY2484595 in Healthy Subjects

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Study of Evacetrapib and Rifampin in Healthy Participants

Healthy Volunteers

United States
The Affiliated Hospital of Xuzhou Medical University

Unknown

Evaluation of Nail Fold Microcirculation in CKD

Chronic Renal Disease

China
Eli Lilly and Company

Terminated

A Study in Migraine Prevention

Migraine Headache

United States, Puerto Rico
Eli Lilly and Company

Completed

PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin

Non Hodgkin Lymphoma

United States, China, Spain, Poland, Taiwan, Belgium, Japan, Germany, Puerto Rico, Australia, France, Sweden, Greece, Italy, India, Czechia, United Kingdom, Canada, Korea, Republic of, Mexico, Denmark, Portugal, Finland, Brazil, Hungary
Eli Lilly and Company

Terminated

A Study of [14C]-LY3023703 in Healthy Participants

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Study of LY3050258 in Healthy Participants

Healthy Participants

United States
Eli Lilly and Company

Completed

A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes

Diabetes Mellitus, Type 2

Singapore
Eli Lilly and Company

Completed

A Study of LY2584702 in Solid Tumors

Cancer

Japan
Eli Lilly and Company

Completed

A Study of Multiple Doses of LY3305677 in Healthy Participants

Healthy

United Kingdom
Eli Lilly and Company

Completed

A Study of LY3007113 in Participants With Advanced Cancer

Metastatic Cancer

United States
Eli Lilly and Company

Completed

A Study of LY3039478 in Participants With Advanced Cancer

Neoplasms | Lymphoma | Neoplasm Metastasis

United States, Spain, Germany, France, United Kingdom, Denmark
Eli Lilly and Company

Completed

A Study for Participants With Advanced Cancer

Metastatic Cancer | Advanced Cancer

United States
Eli Lilly and Company

Completed

A Single Dose Study of LY3023703 in Healthy Participants

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Dose-Escalation Study for Patients With Advanced Cancer

Advanced Cancer

United States
Eli Lilly and Company

Completed

A Study of LY2835219 in Healthy Participants

Healthy Volunteers

United Kingdom
Eli Lilly and Company

Completed

A First Human Study of a Ferroportin Antibody

Healthy Volunteers

Singapore
Eli Lilly and Company

Completed

A Study of LY3084077 in Healthy Participants

Healthy Volunteers

Singapore
Eli Lilly and Company

Completed

A Study of LY3050258 in Healthy Participants

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Study of Multiple Doses of LY2922470 in Participants With Diabetes

Diabetes Mellitus, Type 2

United States

Search clinical trials for: GMT

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kyrgyzstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations